BREAST CANCER

Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.

Phase 3 results from a cohort of patients in China show a progression-free survival benefit with entinostat/exemestane.

Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.

Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.

Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.

Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.

Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.

Research shows that tamoxifen treatment may lead to problems down the road in patients with primary breast cancer.

During a press briefing ahead of the 2021 San Antonio Breast Cancer Symposium, results from the phase 3 EMERALD trial were presented.

Imaging mass cytometry at the single-cell level may be a promising response prediction tool for immunotherapy in early triple-negative breast cancer.

In an epidemiological study, a 24-month lymphedema rate of 39.4% was the highest incidence of lymphedema observed among Black women.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.

Findings from the phase 3 PADA-1 trial reveal promising progression-free survival results when treatment with fulvestrant/palbociclib follows treatment with an aromatase inhibitor plus palbociclib in a metastatic breast cancer subgroup.

Evanthia Roussos Torres, MD, PhD, discusses the follow-up research related to the phase 1 study of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.

Findings from the phase 3 OlympiA led to the filing of a supplemental new drug application for olaparib as adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

The TROPION-Breast01 study aims to enroll 700 patients to determine the safety and efficacy of datopotamab deruxtecan in patients with HR-positive, HER2-negative breast cancer.

Evanthia Roussos Torres, MD, PhD, discusses the phase 1 study of the efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.

A novel liquid biopsy for the detection of early-stage breast cancer has been granted a breakthrough device designation from the FDA.

The phase 2b AIPAC study, Eftilagimod alpha was found to improve overall survival in metastatic breast cancer along with a tolerable safety profile.

Elisa Agostinetto, MD, discusses the next steps in the research into the accuracy of PREDICT+ to predict survival in HER2-positive breast cancer.

Looking at 2 years' worth of data for patients with ERBB2-negative breast cancer, a study showed that the anti-inflammatory agent celecoxib had no disease free survival benefit.

Joseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.

After showing significant improvement in survival, a breakthrough therapy designation application for leronlimab has been submitted to the FDA.

Florida Cancer Specialists & Research Institute, in collaboration with AdventHealth Heart of Florida and Central Florida Cancer Institute, has received a 3-year accreditation from the National Accreditation Program for Breast Centers.

After discovering the potential of a prophylactic breast cancer vaccine, Cleveland Clinic will be the site of a phase 1 clinical trial to test its safety.

Margaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.

The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in postmenopausal patients with breast cancer.

Florida Cancer Specialists & Research Institute has received a three-year accreditation from the National Accreditation Program for Breast Centers.

Both the primary and key secondary end point of the phase 3 EMERALD study have been reached.

In an interview with Targeted Oncology, Evanthia Roussos Torres, MD, PhD, discussed the phase 1 investigation of the safety and efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of advanced HER2-negative breast cancer.